Physician profile
Mark Holbreich
NPI 1427023423
$1,737.37
in general payments reported to CMS, 2019-2025
13 companies · $92.70 in 2025
The $92.70 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $547 · 2020: $281 · 2021: $427 · 2022: $130 · 2023: $109 · 2024: $151 · 2025: $92.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $352.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $387.64 | 2019-2022 | |
| Glaxosmithkline, LLC. | $270.60 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $252.23 | 2019-2024 | Dupixent |
| Novartis Pharmaceuticals Corporation | $144.26 | 2019-2021 | |
| Genentech USA, INC. | $141.57 | 2022-2024 | |
| Genzyme Corporation | $111.16 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $109.85 | 2019-2021 | |
| Blueprint Medicines Corporation | $109.36 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $104.32 | 2020-2022 | |
| Abbvie INC. | $44.16 | 2022 | |
| Pfizer INC. | $22.54 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.54 | 2021 | |
| Sanofi-Aventis U.S. LLC | $19.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Holbreich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.